Recent Progresses in Brain Gene Therapy
International Clinical Neuroscience Journal,
Vol. 3 No. 4 (2016),
7 February 2017
Gene therapy consists of the introduction of genetic material into cells for a therapeutic purpose. The understanding of the basics of the molecular and cellular mechanisms in disease treatments has resulted in the development of high-tech gene transfer materials with improved therapeutic efficacy. Based on the results of more than 2000 clinical trials to date, gene therapy is going to be included in standard treatment approaches in some specific diseases. Also, gene therapy has been highly improved in central and peripheral nervous system diseases. This review tried to focus on techniques and approaches in brain tumors and nervous system’s gene therapy strategies and will discuss about associated problems and potential future in management of inherited or acquired neurological disorders.
- Gene therapy
- Nervous system
How to Cite
Gage FH, Fisher LJ, Jinnah HA, Rosenberg MB, Tuszynski MH, Friedmann T. Grafting genetically modified cells to the brain: conceptual and technical issues. Progress in brain research. 1990 Dec 31;82:1-0.
Sun M. Martin Cline loses appeal on NIH grant. Science (New York, NY). 1982 Oct 1;218(4567):37.
Sheridan C. Gene therapy finds its niche. Nature biotechnology. 2011 Feb 1;29(2):121-8.
Wilson JM. Gendicine: the first commercial gene therapy product; Chinese translation of editorial. Human gene therapy. 2005 Sep 1;16(9):1014-5.
Büning H. Gene therapy enters the pharma market: the short story of a long journey. EMBO molecular medicine. 2013 Jan 3;5(1):1-3.
Raper SE, Yudkoff M, Chirmule N, Gao GP, Nunes F, Haskal ZJ, et al. A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency. Human gene therapy. 2002 Jan 1;13(1):163-75.
Herweijer H, Wolff JA. Progress and prospects: naked DNA gene transfer and therapy. Gene therapy. 2003 Mar 2;10(6):453-8.
Seddighi A, Seddighi AS, Nikouei A, Mohseni G. NS-06IMAGE GUIDED SURGERY USING NEURONAVIGATION SYSTEM IN RESECTION OF CEREBRAL GLIOMAS INVOLVING ELOQUENT CORTICAL AREAS IN PEDIATRIC POPULATION. Neuro-Oncology. 2016 Jun 1;18(suppl 3):iii128-.
Heller LC, Ugen K, Heller R. Electroporation for targeted gene transfer. Expert opinion on drug delivery. 2005 Mar 1;2(2):255-68.
Mc Mahon JM, Wells DJ. Electroporation for gene transfer to skeletal muscles: Current status. Biol Drugs. 2004;18:155–65.
Nayerossadat N, Maedeh T, Ali PA. Viral and nonviral delivery systems for gene delivery. Advanced biomedical research. 2012 Jan 1;1(1):27.
Dewannieux M, Harper F, Richaud A, Letzelter C, Ribet D, Pierron G, et al. Identification of an infectious progenitor for the multiple-copy HERV-K human endogenous retroelements. Genome research. 2006 Dec 1;16(12):1548-56.
Miller DG, Adam MA, Miller AD. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Molecular and cellular biology. 1990 Aug 1;10(8):4239-42.
Danos O, Mulligan RC. Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. Proceedings of the National Academy of Sciences. 1988 Sep 1;85(17):6460-4.
Cideciyan AV, Hauswirth WW, Aleman TS, Kaushal S, Schwartz SB, Boye SL, et al. Vision 1 year after gene therapy for Leber's congenital amaurosis. New England Journal of Medicine. 2009 Aug 13;361(7):725-7.
Ehrhardt A, Yant SR, Giering JC, Xu H, Engler JA, Kay MA. Somatic integration from an adenoviral hybrid vector into a hot spot in mouse liver results in persistent transgene expression levels in vivo. Molecular Therapy. 2007 Jan 1;15(1):146-56.
Seddighi A, Akbari ME, Seddighi AS, Pirayesh E, Soleymani MM, Baqdashti HR, et al. Radioguided surgery using gamma detection probe technology for resection of cerebral glioma. Hellenic journal of nuclear medicine. 2014 Dec;18:68-75.
Wu Z, Asokan A, Samulski RJ. Adeno-associated virus serotypes: vector toolkit for human gene therapy. Molecular therapy. 2006 Sep 1;14(3):316-27.
Goins WF, Goss JR, Chancellor MB, de Groat WC, Glorioso JC, Yoshimura N. Herpes simplex virus vector-mediated gene delivery for the treatment of lower urinary tract pain. Gene therapy. 2009 Apr 1;16(4):558-69.
Seddighi A, Seddighi AS, Nikouei A, Ashrafi F, Nohesara S. Psychological aspects in brain tumor patients: A prospective study. Hellenic journal of nuclear medicine. 2014 Dec;18:63-7.
Bainbridge JW, Smith AJ, Barker SS, Robbie S, Henderson R, Balaggan K, et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. New England Journal of Medicine. 2008 May 22;358(21):2231-9.
Hao S, Mata M, Goins W, Glorioso JC, Fink DJ. Transgene-mediated enkephalin release enhances the effect of morphine and evades tolerance to produce a sustained antiallodynic effect in neuropathic pain. Pain. 2003 Mar 31;102(1):135-42.
Lau D, Harte SE, Morrow TJ, Wang S, Mata M, Fink DJ. Herpes simplex virus vector–mediated expression of interleukin-10 reduces below-level central neuropathic pain after spinal cord injury. Neurorehabilitation and neural repair. 2012 Sep 1;26(7):889-97.
Seddighi A, Nikouei A, Seddighi AS, Zali AR, Tabatabaei SM, Sheykhi AR, et al. Peripheral Nerve Injury: A Review Article. 2016 Jul 9;3(1):1-6.
Marks WJ, Ostrem JL, Verhagen L, Starr PA, Larson PS, Bakay RA, et al. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2–neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. The Lancet Neurology. 2008 May 31;7(5):400-8.
Estin D, Li M, Spray D, Wu JK. Connexins are expressed in primary brain tumors and enhance the bystander effect in gene therapy. Neurosurgery. 1999 Feb 1;44(2):361-8.
Namba H, Tagawa M, Iwadate Y, Kimura M, Sueyoshi K, Sakiyama S. Bystander effect-mediated therapy of experimental brain tumor by genetically engineered tumor cells. Human gene therapy. 1998 Jan 1;9(1):5-11.
Bouvard V, Zaitchouk T, Vacher M, Duthu A, Canivet M, Choisy-Rossi C, et al. Tissue and cell-specific expression of the p53-target genes: bax, fas, mdm2 and waf1/p21, before and following ionising irradiation in mice. Oncogene. 2000 Feb 3;19(5):649-60.
Li H, Alonso-Vanegas M, Colicos MA, Jung SS, Lochmuller H, Sadikot AF, et al. Intracerebral adenovirus-mediated p53 tumor suppressor gene therapy for experimental human glioma. Clinical cancer research. 1999 Mar 1;5(3):637-42.
Asai A, Miyagi Y, Hashimoto H, Lee SH, Mishima K, Sugiyama A, et al. Modulation of tumor immunogenicity of rat glioma cells by s-Myc expression: eradication of rat gliomas in vivo. Cell growth & differentiation: the molecular biology journal of the American Association for Cancer Research. 1994 Nov;5(11):1153-8.
Trojan J, Johnson TR, Rudin SD, Ilan J, Tykocinski ML, Ilan J. Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor 1 RNA. SCIENCE-NEW YORK THEN WASHINGTON-. 1993 Jan 1;259:94.
Tanaka T, Manome Y, Wen P, Kufe DW, Fine HA. Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth. Nature medicine. 1997 Apr;3(4):437-42.
Bovolenta R, Zucchini S, Paradiso B, Rodi D, Merigo F, Mora GN, et al. Hippocampal FGF-2 and BDNF overexpression attenuates epileptogenesis-associated neuroinflammation and reduces spontaneous recurrent seizures. Journal of neuroinflammation. 2010 Nov 18;7(1):1.
- Abstract Viewed: 265 times
- PDF Downloaded: 286 times